Human Health Biotechnology: Can Brazil Advance?

Authors

  • Carlos Torres Freire Cebrap Brazilian Centre for Analysis and Planning
  • Victor Callil Cebrap Brazilian Centre for Analysis and Planning
  • Denise Golgher Symbiosis-Biotechnology

DOI:

https://doi.org/10.5912/jcb670

Keywords:

biotechnology, innovation, research and development, economic growth.

Abstract

The Brazilian human health biotechnology sector was analyzed according to its spacial and sectorial distribution of the following aspects: (i) the scientific production; (ii) dependence of companies on governmental funding for research and development; (iii) the lack of innovative capacity regarding the discovery and development of new drugs and (iv) a disconnection between the advancement of scientific output and innovation within the private sector. The picture depicted suggests that, despite the advances being made in science and technology, it is still necessary to overcome many weaknesses to achieve an economic growth based on knowledge and innovation.

Author Biographies

Carlos Torres Freire, Cebrap Brazilian Centre for Analysis and Planning

 PhD in Sociology at University of Sao Paulo
(USP) and researcher at Brazilian Centre for Analysis and Planning
(Cebrap). Research interests: economic development, focused on
science, technology and innovation (STI), university-enterprises
relationships and biotechnology.

Victor Callil, Cebrap Brazilian Centre for Analysis and Planning

Master’s candidate in Sociology at University of Sao
Paulo and research assistant at the Brazilian Centre for Analysis and
Planning (Cebrap).

Denise Golgher, Symbiosis-Biotechnology

Denise earned a MSc in Biochemistry  from  University  of São Paulo (Brazil), a 
Ph.D. in Cell Biology from  the  Johns Hopkins  University (USA) and completed 
post-doctorate research at University of Oxford (UK).

She  studied  business  at   Fundação  Dom  Cabral  (Brazil)  and has  been  a
biotechnology consultant since 2003.

References

Capes, “GEOCAPES - coordenação de aperfeiçoamento de pessoal de nível superior†http://geocapes.capes.gov.br/geocapesds/, accessed January 2013.

Hollanders, H. and Soete, L. (2010) “O crescente papel do conhecimento na economia globalâ€. In: Relatório UNESCO report about science 2010. Translation by Demerval de Sena Aires Júnior. Sector of Natural Sciences, Unesco Brazil.

MCTI, “Indicadores - Ministério da Ciência, Tecnologia e Inovaçãoâ€, http://www.mct.gov.br, accessed in 01/2013.

Gadelha, Carlos Augusto, Costa, Laís Silveira e Maldonado, José. “O complexo econômico-industrial da saúde e a dimensão social e econômica do desenvolvimentoâ€. Revista Saúde Pública, vol. 46, supl. 1, São Paulo: USP, dez. 2012.

SIR world report 2012: global ranking.

Preliminary data published by SCImago journal & country rank (2012) that were included in the documents that could be quoted ("Citable documents").

Cruz, Carlos Henrique de Brito e Chaimovich, Hernan. (2010) “Brasilâ€. In: Relatório UNESCO sobre ciência 2010. Translation by Demerval de Sena Aires Júnior. Sector of Natural Sciences, Unesco Brazil.

Fapesp (2011). “Indicadores de CT&I em saúde no estado de São Pauloâ€. In: Indicadores de ciência, tecnologia e inovação em São Paulo 2010, São Paulo.

Fapesp (2011). “Atividade de patenteamento no Brasil e no exteriorâ€. In: Indicadores de ciência, tecnologia e inovação em São Paulo 2010, São Paulo.

http://download.finep.gov.br/programas/inovar/Resultados.pdf, accessed on 03/02/2014.

Huggett, B. (2013) Public biotech 2012 – the numbers. Nature biotechnology 31(8): 697–703.

Gadelha, Carlos Augusto. “Desenvolvimento, complexo industrial da saúde e política industrialâ€. Revista Saúde Pública, n. 40, São Paulo: USP, 2006, pp. 11-23.

Gadelha, Carlos Augusto, Quental, Cristiane e Fialho, Beatriz de Castro. “Saúde e inovação: uma abordagem sistêmica das indústrias da saúdeâ€. Cad. Saúde Pública, Rio de Janeiro, 19(1), jan.-fev., 2003, pp. 47-59. Fapesp. “Indicadores de CT&I em saúde no estado de São Pauloâ€. In: Indicadores de ciência, tecnologia e inovação em São Paulo 2010. São Paulo: Fapesp, 2011.

Rezaie, R., Frew S.E., Sammut, S.M., Maliakkal, M.R., Daar, A.S. and Singer P.A. (2008). Brazilian health biotech – fostering crosstalk between public and private sectors. Nature Biotechnology 26: 627-644.

Shadlen, Kenneth e Fonseca, Elize Massard. “Health Policy as Industrial Policy: Brazil in Comparative Perspectiveâ€. Politics & Society. London: sage Publications, v. 41, n. 4, p. 561‑587, 2013.

Costa, Laís Silveira, Gadelha, Carlos Augusto e Metten, Antoine. “Saúde e desenvolvimento no Brasil: estado da arte e desafiosâ€. In: Jornada nacional de economia da saúde, 6ª edição, Brasília, 2012.

Ministério da Saúde, 2013: http://www.brasil.gov.br/saude/2013/12/brasil-vai-desenvolver-19-novos-produtos-de-saude, accessed on 12/12/2013.

http://www.planalto.gov.br/ccivil_03/_Ato2011-2014/2012/Decreto/D7713.htm

Schmidt, M.I, Duncan, B.B., Azevedo e Silva, G., Menezes, A.M. Monteiro, C.A., Barreto, S.M., Chor, D. And Menezes, P.R. (2011) Chronic non-communicable diseases in Brazil. The Lancet 377:1949-1961.

Published

2015-04-01

Issue

Section

Articles